2 min readProton Therapy Offers New, Precise Cancer Treatment for Children With High-Risk Neuroblastoma
Philadelphia, PA – Proton therapy, using high-energy subatomic particles, may offer a precise, organ-sparing treatment option for children with high-risk forms of neuroblastoma. For patients in a new study of advanced radiation treatment, proton therapy spared the liver and kidneys from unwanted radiation, while zeroing in on its target.
“As survival rates improve for children with neuroblastoma, we need to reduce treatment-related long-term toxicities,” said study leader Dr. Christine Hill-Kayser, a radiation oncologist in the cancer centre at The Children’s Hospital of Philadelphia (CHOP). “Proton beam therapy offers precise targeting with less radiation exposure to healthy tissue.”
Hill-Kayser and colleagues published their study online June 4, 2013 in Pediatric Blood & Cancer.
Owing to collaboration between Children’s Hospital and radiation oncologists at Penn Medicine, the Roberts Proton Therapy Center, where the study was conducted, is the first proton therapy facility in the U.S. conceived with paediatric patients in mind from the earliest planning stages.
Protons, the positively charged particles in an atom’s nucleus, are used in therapy to destroy DNA in tumours and prevent cancer cells from multiplying. In children, this therapy is often used against spinal tumours. CHOP has recently been directing protons at neuroblastoma, long a special focus of the Hospital’s clinical and research programs.
Neuroblastoma, the most common solid tumour of early childhood, strikes the peripheral nervous system, usually appearing as a solid tumour in a young child’s chest or abdomen.
Paediatric oncologists have an arsenal of weapons against neuroblastoma, but high-risk forms of this cancer present a particular challenge, often frustrating conventional treatment from the start or recurring in a resistant form.
The current study, said Hill-Kayser, included 13 children with a median age of 3 years who responded well to initial chemotherapy, followed by surgery, more chemotherapy, bone marrow transplant, and in some cases, immunotherapy. The advanced radiation treatment aimed to destroy remaining microscopic areas of cancer cells while minimizing toxicity to healthy tissue.
In planning radiation treatment for each child, the study team determined that 11 patients should receive proton therapy, and that two other patients, because of their specific anatomy and the location of their tumours, should receive intensity-modulated X-ray therapy (IMXT). In IMXT, radiologists sculpt the radiation emitted from 7 different angles to modify radiation dosages in and around the targeted area.
None of the 13 patients had local disease recurrence or acute organ toxicity. For 11 of them, proton therapy provided the best combination of target coverage and organ sparing. “Protons are heavier than the particles in X-rays and have more stopping power,” said Hill-Kayser. “They deposit 90 percent of their energy precisely at the tumour site, with nearly zero radiation away from the tumour. That protects healthy organs — which, as growing tissues, are especially vulnerable to radiation damage in young children.”
The fact that individual characteristics made IMXT preferable to proton therapy in two children, said Hill-Kayser, underscores the need to meticulously customize radiation treatment to each patient. Overall, the current study shows that proton therapy should be considered for children with high-risk neuroblastoma. She added, “To better assess the use of proton therapy against high-risk neuroblastoma, we’ll need to study larger numbers of patients and do long-term follow-up. However, this represents a great start.”
Publication: Proton versus Photon Radiation Therapy for Patients with High-Risk Neuroblastoma: The Need for a Customized Approach. Hill-Kayser et al. Pediatric Blood & Cancer (June 4, 2013): http://onlinelibrary.wiley.com/doi/10.1002/pbc.24606/abstract